Dr. Shi-He Liu's lab at the University of Toledo focuses on developing advanced delivery systems for targeted cancer therapies, especially for pancreatic cancer. They are engineering exosomes, which are tiny vesicles that can carry drugs or genes to specific cells. The goal is to improve the accuracy and effectiveness of cancer treatments while reducing side effects. Their innovative approaches may lead to significant breakthroughs in cancer medicine.

Bruce A Bamber's lab at the University of Toledo focuses on understanding how our sense of smell influences behavior and physiological responses using the model organism C. elegans. The lab studies how olfactory information is processed and encoded through a combinatorial coding mechanism, with the aim of uncovering the underlying principles of olfactory processing. Undergraduate students play a pivotal role in the research, gaining hands-on experience and contributing to key experiments.

Dr. Dayanidhi Raman's lab focuses on understanding how certain proteins in breast cancer cells contribute to drug resistance, particularly in aggressive forms like triple-negative breast cancer (TNBC). By studying a protein called eIF4A1, the lab seeks to find ways to target and eliminate drug-resistant cancer stem cells to improve treatment outcomes. The goal is to develop new therapies that can effectively combat this challenging disease and prevent tumor recurrence.

Dr. Jian-Ting Zhang's lab focuses on developing new treatment strategies for triple-negative breast cancer (TNBC), a type of breast cancer that often resists existing therapies. The lab is investigating how fatty acid synthase (FASN) contributes to resistance against certain cancer drugs and exploring the potential of combining proton pump inhibitors with these drugs to enhance their effectiveness. By targeting FASN, the lab aims to improve survival rates and reduce the side effects of current treatments for TNBC patients.

Dr. Jianmin Zhang's lab at the University of Toledo focuses on understanding the complex interactions between tumors and the immune system, specifically in triple-negative breast cancer (TNBC). The lab investigates how a protein called TAZ influences the behavior of immune cells in the tumor environment, potentially leading to new targets for treatment in this aggressive form of breast cancer. Their research aims to uncover mechanisms that could improve patient outcomes by identifying novel biomarkers and therapeutic strategies.